| ◆英語タイトル：Global Vasculitis Treatment Market Size study & Forecast, by Drug Class (Biologics, Corticosteroids and immunosuppressants), by Disease Type (Small and medium vessel vasculitis, Large vessel vasculitis), by Distribution Channel (Hospital Pharmacies, Drug stores and retail pharmacies, Online Pharmacies) and Regional Analysis, 2022-2029
|
 | ◆商品コード：BZW23FE0070
◆発行会社（リサーチ会社）：Bizwit Research & Consulting
◆発行日：2023年2月8日
◆ページ数：約200
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後3営業日）
◆調査対象地域：アメリカ、カナダ、イギリス、ドイツ、フランス、スペイン、イタリア、中国、インド、日本、オーストラリア、韓国、ブラジル、メキシコ、中東
◆産業分野：医療
|
◆販売価格オプション
（消費税別）
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
Bizwit Research社の本調査レポートでは、2021年に250.1百万ドルであった世界の血管炎治療市場規模が、2022年から2029年の間に3.4%で拡大すると見込んでいます。本書は、血管炎治療の世界市場を徹底調査しており、エグゼクティブサマリー、市場定義・範囲、市場動向、産業分析、リスク分析（新型コロナウイルス感染症の影響）、治療薬クラス別（生物製剤、コルチコステロイド、免疫抑制剤）分析、疾患別（小・中血管炎、大血管炎）分析、流通チャネル別（病院薬局、ドラッグストア・小売薬局、オンライン薬局）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、その他）分析、競争分析、調査プロセスなどを整理しています。また、本書内には、Amneal Pharmaceuticals Inc.、AstraZeneca plc、 F. Hoffmann-La Roche Ltd、 GlaxoSmithKline plc、Pfizer Inc.、 InflaRx N.V、 Novartis AG、 ChemoCentryx Inc. 、 AbbVie Inc. 、 Teva Pharmaceutical Industries Ltd.などの企業情報が含まれています。
・エグゼクティブサマリー
・市場定義・範囲
・市場動向
・産業分析
・リスク分析（新型コロナウイルス感染症の影響）
・世界の血管炎治療市場規模：治療薬クラス別
- 生物製剤の市場規模
- コルチコステロイドの市場規模
- 免疫抑制剤の市場規模
・世界の血管炎治療市場規模：疾患別
- 小・中血管炎における市場規模
- 大血管炎における市場規模
・世界の血管炎治療市場規模：流通チャネル別
- 病院薬局チャネルの市場規模
- ドラッグストア・小売薬局チャネルの市場規模
- オンライン薬局チャネルの市場規模
・世界の血管炎治療市場規模：地域別
- 北米の血管炎治療市場規模
- ヨーロッパの血管炎治療市場規模
- アジア太平洋の血管炎治療市場規模
- 中南米の血管炎治療市場規模
- その他地域の血管炎治療市場規模
・競争分析
・調査プロセス |
Global Vasculitis Treatment Market is valued at approximately USD 250.1 million in 2021 and is anticipated to grow with a healthy growth rate of more than 3.4% over the forecast period 2022-2029. Vasculitis Treatment is a rare inflammatory disease which affects blood vessels. The inflammation causes the walls of the blood vessels to thicken, which shortens the width of the passageway through the vessel and restricts blood flow. Moreover, restricted blood flow can result in organ failure and tissue damage. There are many types of vasculitis, such as Giant cell arteritis (GCA), Takayasu’s arteritis (TAK), Aortitis, Kawasaki disease (KD), and Polyarteritis nodosa (PAN) among others. The general symptoms and signs of Vasculitis include Fever, Headache, Fatigue, Weight loss, General aches, pains, etc. The increasing vasculitis prevalence and growing incidences of chronic diseases as well as strategic initiatives from leading market players are key factors accelerating the market growth.
The increasing incidences of vasculitis prevalence are contributing towards the growth of the Global Vasculitis Treatment Market. For instance – according to Vasculitis UK – as of 2020, vasculitis affects 2000 to 3000 UK residents every year. Moreover, as per American Heart Association Journal – as of January 2021, in Sweden and Norway more than 20 new cases of GCA per 100 000 individuals aged 50 years and older are reported every year. Additionally, the lifetime risk of developing GCA is estimated at 1% for women and 0.5% for men in the United States. Also, the rapid growth of active pharmaceutical ingredient (API) industry and rising healthcare infrastructure in developing regions would create a lucrative growth prospectus for the market over the forecast period. However, side effects associated with corticosteroids and unfavorable reimbursement scenarios stifle market growth throughout the forecast period of 2022-2029.
The key regions considered for the Global Vasculitis Treatment Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to the presence of leading market players and increasing incidences of vasculitis in the region. Whereas Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as rising geriatric populations, and increasing expansion of pharmaceuticals manufacturing sector in the region.
Major market players included in this report are:
Amneal Pharmaceuticals Inc.
AstraZeneca plc
F. Hoffmann-La Roche Ltd
GlaxoSmithKline plc
Pfizer Inc.
InflaRx N.V
Novartis AG
ChemoCentryx Inc.
AbbVie Inc.
Teva Pharmaceutical Industries Ltd.
Recent Developments in the Market:
In September 2021, Vifor Fresenius Medical Care Renal Pharma (VFMCRP) announced that Japan’s Ministry of Health and Labor Welfare (MHLW) has granted its partner, Kissei Pharmaceutical Co., Ltd., approval for marketing of TAVNEOS® for the treatment of patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA).
In October 2022, Amgen completed its planned acquisition of ChemoCentryx, Inc. for a transaction value of USD 3.7 billion. This acquisition also includes TAVNEOS, an orally administered inhibitor that was approved by the U.S. Food and Drug Administration (FDA) in October 2021 for the treatment of severe active ANCA-associated vasculitis.
Global Vasculitis Treatment Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Drug Class, Disease Type, Distribution Channel, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Drug Class
Biologics
Corticosteroids and immunosuppressants
By Disease Type
Small and medium vessel vasculitis
Large vessel vasculitis
By Distribution Channel
Hospital pharmacies
Drug stores and retail pharmacies
Online Pharmacies
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World
Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Million)
1.2.1. Vasculitis Treatment Market, by Region, 2019-2029 (USD Million)
1.2.2. Vasculitis Treatment Market, by Drug Class, 2019-2029 (USD Million)
1.2.3. Vasculitis Treatment Market, by Disease Type, 2019-2029 (USD Million)
1.2.4. Vasculitis Treatment Market, by Distribution Channel, 2019-2029 (USD Million)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Vasculitis Treatment Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Vasculitis Treatment Market Dynamics
3.1. Vasculitis Treatment Market Impact Analysis (2019-2029)
3.1.1. Market Drivers
3.1.1.1. Increasing vasculitis prevalence
3.1.1.2. Growing incidences of chronic diseases
3.1.1.3. Strategic initiatives from leading market players
3.1.2. Market Challenges
3.1.2.1. Side effects associated with corticosteroids
3.1.2.2. Unfavourable reimbursement scenario
3.1.3. Market Opportunities
3.1.3.1. Growing active pharmaceutical ingredient (API) industry
3.1.3.2. Rising healthcare infrastructure in developing regions
Chapter 4. Global Vasculitis Treatment Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Futuristic Approach to Porter’s 5 Force Model (2019-2029)
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.4. Top investment opportunity
4.5. Top winning strategies
4.6. Industry Experts Prospective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Risk Assessment: COVID-19 Impact
5.1. Assessment of the overall impact of COVID-19 on the industry
5.2. Pre COVID-19 and post COVID-19 Market scenario
Chapter 6. Global Vasculitis Treatment Market, by Drug Class
6.1. Market Snapshot
6.2. Global Vasculitis Treatment Market by Drug Class, Performance – Potential Analysis
6.3. Global Vasculitis Treatment Market Estimates & Forecasts by Drug Class 2019-2029 (USD Million)
6.4. Vasculitis Treatment Market, Sub Segment Analysis
6.4.1. Biologics
6.4.2. Corticosteroid
6.4.3. Immunosuppressants
Chapter 7. Global Vasculitis Treatment Market, by Disease Type
7.1. Market Snapshot
7.2. Global Vasculitis Treatment Market by Disease Type, Performance – Potential Analysis
7.3. Global Vasculitis Treatment Market Estimates & Forecasts by Disease Type 2019-2029 (USD Million)
7.4. Vasculitis Treatment Market, Sub Segment Analysis
7.4.1. Small and medium vessel vasculitis
7.4.2. Large vessel vasculitis
Chapter 8. Global Vasculitis Treatment Market, by Distribution Channel
8.1. Market Snapshot
8.2. Global Vasculitis Treatment Market by Distribution Channel, Performance – Potential Analysis
8.3. Global Vasculitis Treatment Market Estimates & Forecasts by Distribution Channel 2019-2029 (USD Million)
8.4. Vasculitis Treatment Market, Sub Segment Analysis
8.4.1. Hospital pharmacies
8.4.2. Drug store and retail pharmacies
8.4.3. Online Pharmacies
Chapter 9. Global Vasculitis Treatment Market, Regional Analysis
9.1. Vasculitis Treatment Market, Regional Market Snapshot
9.2. North America Vasculitis Treatment Market
9.2.1. U.S. Vasculitis Treatment Market
9.2.1.1. Drug Class breakdown estimates & forecasts, 2019-2029
9.2.1.2. Disease Type breakdown estimates & forecasts, 2019-2029
9.2.1.3. Distribution Channel breakdown estimates & forecasts, 2019-2029
9.2.2. Canada Vasculitis Treatment Market
9.3. Europe Vasculitis Treatment Market Snapshot
9.3.1. U.K. Vasculitis Treatment Market
9.3.2. Germany Vasculitis Treatment Market
9.3.3. France Vasculitis Treatment Market
9.3.4. Spain Vasculitis Treatment Market
9.3.5. Italy Vasculitis Treatment Market
9.3.6. Rest of Europe Vasculitis Treatment Market
9.4. Asia-Pacific Vasculitis Treatment Market Snapshot
9.4.1. China Vasculitis Treatment Market
9.4.2. India Vasculitis Treatment Market
9.4.3. Japan Vasculitis Treatment Market
9.4.4. Australia Vasculitis Treatment Market
9.4.5. South Korea Vasculitis Treatment Market
9.4.6. Rest of Asia Pacific Vasculitis Treatment Market
9.5. Latin America Vasculitis Treatment Market Snapshot
9.5.1. Brazil Vasculitis Treatment Market
9.5.2. Mexico Vasculitis Treatment Market
9.5.3. Rest of Latin America Vasculitis Treatment Market
9.6. Rest of The World Vasculitis Treatment Market
Chapter 10. Competitive Intelligence
10.1. Top Market Strategies
10.2. Company Profiles
10.2.1. Amneal Pharmaceuticals Inc.
10.2.1.1. Key Information
10.2.1.2. Overview
10.2.1.3. Financial (Subject to Data Availability)
10.2.1.4. Product Summary
10.2.1.5. Recent Developments
10.2.2. AstraZeneca plc
10.2.3. F. Hoffmann-La Roche Ltd
10.2.4. GlaxoSmithKline plc
10.2.5. Pfizer Inc.
10.2.6. InflaRx N.V
10.2.7. Novartis AG
10.2.8. ChemoCentryx Inc.
10.2.9. AbbVie Inc.
10.2.10. Teva Pharmaceutical Industries Ltd.
Chapter 11. Research Process
11.1. Research Process
11.1.1. Data Mining
11.1.2. Analysis
11.1.3. Market Estimation
11.1.4. Validation
11.1.5. Publishing
11.2. Research Attributes
11.3. Research Assumption
❖ 免責事項 ❖http://www.globalresearch.jp/disclaimer